Abstract
This review discusses clinical presentation of DAH, diagnosis of the underlying histology’s, treatment options, as well as morbidity and mortality rates. Diffuse alveolar hemorrhage (DAH) is considered a life-threatening pulmonary complication in patients with systemic autoimmune disorders, hematologic malignancies, and coagulation disorders. DAH is distinguished by acute onset of hypoxia and alveolar infiltrates that may lead to progressive alveolar bleeding. Early diagnosis and recognition are crucial for survival. Treatment for DAH involves treating both the underlying condition and the autoimmune damage of the alveolar capillary membrane. The gold standard is immunosuppressive agents and corticosteroids. Despite early recognition and proper treatment DAH mortality rates remain high.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Lung, Pulmonary & Respiratory Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
